C4 Therapeutics (CCCC) Retained Earnings (2019 - 2026)

C4 Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$763.8 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 15.73% year-over-year to -$763.8 million; the TTM figure through Mar 2026 stood at -$763.8 million (down 15.73% YoY), while the FY2025 annual figure was -$738.7 million, down 1393860.38% from the prior year.
• Retained Earnings was -$763.8 million for Q1 2026 at C4 Therapeutics, down from -$738.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $53000.0 in Q4 2024 to a low of -$763.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$332.7 million across 5 years, with a median of -$358.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 100.01% in 2024, then tumbled 1393860.38% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$395.9 million in 2022, then plunged by 33.47% to -$528.4 million in 2023, then soared by 100.01% to $53000.0 in 2024, then sank by 1393860.38% to -$738.7 million in 2025, then declined by 3.4% to -$763.8 million in 2026.
• The last three Retained Earnings figures came in at -$763.8 million (Q1 2026), -$738.7 million (Q4 2025), and -$718.2 million (Q3 2025), per Business Quant data.